Louis Kayitalire

Insider Reports History

Entity
Individual
Location
C/O Eddeva B920, Babraham Research Campus, Cambridge, United Kingdom
Signature
/s/ Darlene Deptula-Hicks, Attorney-in-fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Louis Kayitalire:

Stock Role Class Num Shares Value Price $ Report Date Ownership
F-star Therapeutics, Inc. CHIEF MEDICAL OFFICER Common Stock 0 $7.12 Mar 8, 2023 Direct
F-star Therapeutics, Inc. CHIEF MEDICAL OFFICER Stock Option (right to buy) 0 Mar 8, 2023 Direct

Insider Reports Filed by Louis Kayitalire

Symbol Company Period Transactions Value $ Form Type Date Filed Role
FSTX F-star Therapeutics, Inc. Mar 8, 2023 6 -$386K 4 Mar 9, 2023 CHIEF MEDICAL OFFICER
FSTX F-star Therapeutics, Inc. Mar 31, 2022 1 $0 4 Apr 4, 2022 Chief Medical Officer
FSTX F-star Therapeutics, Inc. Jan 9, 2022 1 $0 4 Jan 11, 2022 Chief Medical Officer
FSTX F-star Therapeutics, Inc. Nov 2, 2021 2 -$437 4 Nov 4, 2021 Chief Medical Officer
FSTX F-star Therapeutics, Inc. Oct 4, 2021 1 -$462 4 Oct 6, 2021 Chief Medical Officer
FSTX F-star Therapeutics, Inc. Jul 2, 2021 1 -$8.89K 4 Jul 7, 2021 Chief Medical Officer
FSTX F-star Therapeutics, Inc. Nov 20, 2020 1 $0 4/A Aug 24, 2021 Chief Medical Officer